Jefferies downgrades Artiva Biotherapeutics stock rating to hold
Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.
How this was made
The 30-second read
Why it matters
The news directly reduces the company's growth outlook and may trigger further sell‑offs in the biotech sector.
Market read
Downgrade and trial termination are material events for ARTV, likely driving short‑term price weakness.
What to watch
Strong cash position and high current ratio could support a strategic sale or partnership despite the program halt.
Background
Artiva Biotherapeutics announced the cessation of its AlloNK autoimmune program after two Grade 5 events and lack of durable response, prompting analyst downgrades.
Ticker impact
Jefferies downgraded Artiva Biotherapeutics to Hold and announced the discontinuation of its AlloNK program, causing a 31% price drop.
likely pressure as investors price in reduced pipeline prospects and lower growth outlook
Analyst downgrade combined with termination of a late‑stage trial signals a material setback for the biotech's valuation.
Market effects
May weigh on other cell‑therapy biotech stocks as investors reassess clinical risk.
Limited to US‑listed biotech sector.
Low; impact confined to niche therapeutic space.
Counterpoint
Cantor Fitzgerald and H.C. Wainwright maintain bullish price targets, suggesting upside if the company can pivot its pipeline.
Key entities
- companyArtiva Biotherapeutics
US‑listed biotech developing cell‑therapy products.
- analystJefferies
Equity research firm that downgraded ARTV.




